{"id":"W4401406952","doi":"10.1136/jitc-2024-008872","title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Department of Science and Technology, Ministry of Science and Technology, India; MacroGenics; Genentech; Actuate Therapeutics; Pfizer; Incyte; Mylan; BeiGene; Clovis Oncology; National Medical Research Council; Exelixis; Karyopharm Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Astex Pharmaceuticals; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002327374,0.002317269,0.003128694,0.0005471123,0.0004240355,0.001185901,0.00108469,0.001585118,0.00829232],"category_scores_gemma":[0.001798716,0.001082228,0.001458717,0.0004328049,0.00143311,0.001478016,0.0005540169,0.002820506,0.001378469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001284315,"about_ca_system_score_gemma":0.001765746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008091974,"about_ca_topic_score_gemma":0.002467579,"domain_scores_codex":[0.9990239,0.0005169995,0.00003989479,0.0002182177,0.00006519017,0.0001357777],"domain_scores_gemma":[0.9988368,0.0003086526,0.000265789,0.00009693797,0.00006624561,0.0004256908],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9659883,0.01854834,0.00118007,0.0002383656,0.0005236362,0.00004384003,0.00005159814,0.0003576882,0.003185306,0.0001010247,0.0007135661,0.00906826],"study_design_scores_gemma":[0.9321785,0.06524774,0.001201694,0.000008374831,0.0001724759,0.00002568495,0.00001152375,0.0003763124,0.0002464611,0.000109049,0.0004129831,0.000009202551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851784,0.001530206,0.000751444,0.0005403158,0.0004628823,0.008010638,0.001433186,0.0001302046,0.001962646],"genre_scores_gemma":[0.9795195,0.001152877,0.002339022,0.001360539,0.0006032183,0.009859509,0.0017723,0.00003445086,0.003358593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00829232,"threshold_uncertainty_score":0.02774054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03115629800748777,"score_gpt":0.3873314010086448,"score_spread":0.356175103001157,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}